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Objective To assess medical resource utilization associated with Prader-Willi syndrome (PWS) in the US, hypoth-
esized to be greater relative to a matched control group without PWS.
Study design We used a retrospective case-matched control design and longitudinal US administrative claims
data (MarketScan) during a 5-year enrollment period (2009-2014). Patients with PWS were identified by Classifica-
tion of Diseases, Ninth Revision, Clinical Modification diagnosis code 759.81. Controls were matched on age, sex,
and payer type. Outcomes included total, outpatient, inpatient and prescription costs.
Results After matching and application of inclusion/exclusion criteria, we identified 2030 patients with PWS (1161
commercial, 38 Medicare supplemental, and 831 Medicaid). Commercially insured patients with PWS (median age
10 years) had 8.8-times greater total annual direct medical costs than their counterparts without PWS (median age
10 years: median costs $14 907 vs $819; P < .0001; mean costs: $28 712 vs $3246). Outpatient care comprised the
largest portion of medical resource utilization for enrollees with and without PWS (median $5605 vs $675; P < .0001;
mean $11 032 vs $1804), followed by mean annual inpatient and medication costs, which were $10 879 vs $1015
(P < .001) and $6801 vs $428 (P < .001), respectively. Total annual direct medical costs were 42% greater for
Medicaid-insured patients with PWS than their commercially insured counterparts, an increase partly explained
by claims for Medicaid Waiver day and residential habilitation.
Conclusion Direct medical resource utilization was considerably greater among patients with PWS than mem-
bers without the condition. This study provides a first step toward quantifying the financial burden of PWS posed
to individuals, families, and society. (J Pediatr 2016;175:137-43).P
rader-Willi syndrome (PWS) is a complex genetic, chronic, life-threatening disorder presenting in childhood with a
prevalence at live birth estimated to range from 1 in 10 000 to 1 in 30 000.1-3 Individuals born with PWS experience
a wide variety of medical challenges throughout their lifetime, generating a burden that is likely considerable and spread
across medical, nonmedical, productivity, and intangible costs.3,4
One of the hallmarks of PWS is hyperphagia, which typically presents as an overriding physiological drive to eat and results in
potentially fatal food-seeking behaviors. If unchecked, it may lead to a variety of sequelae and comorbidities.5
In addition to hyperphagia, patients with PWS also experience serious physiological and developmental deficiencies.4,6-9
Infants classically have hypotonia and poor suck, which may warrant the placement of a nasogastric tube along with addi-
tional perinatal follow-up care. Severe cases may be cared for in the neonatal intensive care unit for weeks to months.1 Hy-From the 1Health Advances LLC, Weston, MA; 2Zafgen,
Boston, MA; 3Niecko Health Economics, LLC, St Pete
Beach, FL; 4Department of Medicine, University of
Alabama at Birmingham, Birmingham, AL; 5Division of
Pediatric Endocrinology, University of Florida College of
Medicine, Gainesville, FL; 6Division of Endocrinology,
Harvard Medical School, Boston Children’s Hospital,
Boston, MA; and 7Division of Research and Genetics,
Departments of Psychiatry & Behavioral Sciences and
Pediatrics, Kansas University Medical Center, Kansas
City, KS
Funded by Zafgen, Boston, MA, a company that is
developing a product to treat individuals with Prader-Willipogonadism and growth hormone deficiency may lead to poor skeletal growth,
short stature, immature appearance, and osteoporosis. Although recombinant
human growth hormone (rhGH) replacement therapy may improve lean
body mass and linear growth, it does not have any clinical impact on the hy-
perphagia in PWS.10 Other medical issues that frequently arise include dental
anomalies, scoliosis, skin picking, strabismus, sleep disturbances and apnea,
and psychiatric disturbances.
We sought to understand the impact of PWS on direct medical costs in the US.
Using a nationally representative US administrative health care claims database,
we estimated the medical resource utilization for individuals in the US with a
medical diagnosis of PWS compared with individuals without PWS.syndrome. A.S., J.G., and D.D. are employed by Health
Advances, LLC, a company that has received consulting
fees from Zafgen. N.K. is employed by Zafgen. The other
authors declare no conflicts of interest.
Portions of the study were presentedat the PWS Asso-
ciation Scientific Day, Orlando, FL, November 5, 2015,
and JP Morgan Healthcare Conference, San Fransisco,
CA, January 14, 2016.
0022-3476/ª 2016 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.jpeds.2016.05.018
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification
LOS Length of stay
PPPY Per-person per-year
PWS Prader-Willi syndrome
rhGH Recombinant human growth hormone
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We used commercial, Medicare supplemental, and Medicaid
data from the MarketScan Research Databases (Truven
Health Analytics, Ann Arbor, Michigan) for the years 2009-
2014. These data provide a cross-sectional and longitudinal
view of health care utilization, expenditures, demographics,
and enrollment in the US. Specifically, the databases contain
deidentified health insurance enrollment information and
fully adjudicated claims data for inpatient and outpatient
medical services as well as outpatient medications. The com-
mercial database includes claims from individuals covered by
employer-sponsored private health insurance. The Medicare
database contains data from retirees with Medicare supple-
mental insurance paid by employers.
Several characteristics set the MarketScan Databases apart
from other similar datasets. The core MarketScan Databases
contain more than 180 million patients since 1995 and
include private sector health data from approximately 100
payers. Moreover, the MarketScan Medicaid Database con-
tains the pooled health care experience of approximately 6
million Medicaid enrollees from multiple states. Historically,
more than 500 million claim records are available in theMar-
ketScan Databases.
This study used a case-matched control design to quantify
health care utilization among patients with PWS compared
with those without the condition. We used the International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) code (759.81), which is specific to PWS,
to identify the PWS case cohort, and conversely, the absence
of the code to define control cohort without PWS. Patients
with PWS initially were identified as having at least 1 match-
ing ICD-9-CM code 759.81 within the given study period.
Matching controls were matched at a 5:1 ratio to cases with
PWS, on the variables of sex, age, and payer type (commer-
cial, Medicare supplemental, and Medicaid). After the initial
data extract, we applied additional criteria to increase the
robustness of our sample.
To account for extraneous coding errors, we included only
cases for which there were at least 2 PWS diagnoses on sepa-
rate dates. Even though the MarketScan Lab Database in-
cludes laboratory test results that could ideally be used to
validate diagnosis, these tests are only captured within the pa-
tients’ enrollment timeframe in our study (maximum 5 years,
2009-2014) and would therefore exclude the patients who
became enrolled after their primary diagnosis occurred and
would have significantly limited our study population.
Finally, we also required patients to be continuously enrolled
for at least 12 months within the 5-year study window, which
helped to ensure that measured healthcare utilization was not
affected by gaps in insurance coverage.
Statistical Analyses
Outpatient service frequency was calculated on the basis of
the number of claims reported; outpatient provider visits,
as well as emergency department visits, and other billable138services were included in this variable. Average component
costs associated with inpatient admissions, outpatient ser-
vices, and prescription medication claims were calculated
for individuals with and without PWS. To account for bias
in the results caused by differences in lengths of continuous
enrollment, utilization statistics were calculated on a per-
person per-year (PPPY) basis. Mean and median costs and
cost ratios were derived for both patients with PWS and their
matched controls. Median costs reflect a typical or standard
patient, whereas mean costs may be more relevant for assess-
ments of total costs. Because payers are responsible for paying
claims for both typical and outlier cases, we have primarily
reported mean costs here.
Statistical tests were performed on costs with theWilcoxon
rank-sum test. Statistics on demographics results in the Table
were run with c2 (categorical variables) and t tests
(continuous variables). To study the baseline level of
comorbidity in each of the study cohorts, we used a
modified Elixhauser methodology to produce a composite
comorbidity score from a list of 31 chronic diseases
identified by ICD-9-CM codes.11,12 Statistical analysis was
performed with SAS version 9.4 (SAS Institute, Cary, North
Carolina).Results
We identified 2030 individuals with PWS who met the dual
PWS diagnosis code and 12-month continuous enrollment
inclusion criteria (1161 commercial, 38 Medicare supple-
mental, and 831Medicaid). Because of the low number of pa-
tients with PWS in the dataset with Medicare supplemental
insurance, for these analyses we combined them with the
commercial plan patients in the 65+ age cohort. After we
matched and applied continuous enrollment criteria, our da-
taset included 6537 controls without PWS (3945 commer-
cial/Medicare supplement and 2592 Medicaid). Sample
demographics are shown after matching and exclusion
criteria were applied (Table).
Very little variation was observed between the demo-
graphic makeup of cohorts with and without PWS, demon-
strating effective matching. Of note, 69% of patients with
PWS were younger than the age of 18 years (mean: 16 years,
commercial/Medicare supplemental; mean: 19 years,
Medicaid). Additionally, patients with PWS had longer
continuous enrollment duration vs controls without PWS
(mean 3.0 vs 2.6 years, commercial/Medicare supplemental;
and mean: 4.0 vs 2.6 years, Medicaid). The mean modified
Elixhauser composite score was 2.38 for PWS and 0.62 for
subjects without PWS with commercial insurance. For the
population insured by Medicaid, these scores were 3.92 for
subjects with PWS and 1.34 for subjects without PWS.
Prescription medication costs were 15.9 times greater for
commercially insured patients with PWS and 7.6 times
greater for Medicaid-insured patients with PWS (all-age, ra-
tio of PWS to without PWS). The mean PPPY cost for pre-
scription medications for individuals with PWS varied byShoffstall et al
Table. Subject demographics after matching and application of exclusion criteria (at least 2 ICD-9-CM codes for PWS
and 12 months continuous enrollment)
n




P value1199 3945 831 2592
Sex
Male 49.9% 49.7% .920 52.8% 53.5% .731
Female 50.1% 50.3% 47.2% 46.5%
Age distribution, y
0-1 12.7% 11.0% .694 14.1% 13.2% .003
2-4 13.6% 13.2% 8.5% 10.5%
5-11 26.8% 28.2% 17.6% 19.3%
12-17 16.5% 16.1% 12.2% 14.4%
18-25 12.9% 13.4% 16.2% 11.5%
26-40 9.0% 8.6% 19.6% 17.5%
41-64 5.8% 6.4% 10.5% 11.3%
65+ 2.8% 3.2% 1.3% 2.3%
Age, y, at start of continuous enrollment
Mean (SD) 15.6 (16.8) 16.3 (17.7) .209 19.4 (16.6) 19.3 (17.7) .924
Median (Min, Max) 10 (0, 92) 11 (0, 95) 17 (0, 90) 14 (0, 90)
Number of continuously enrolled months
Mean (SD) 36.1 (16.3) 30.8 (15.4) <.001 48.2 (17.0) 31.5 (17.8) <.001
Median (min, max) 36 (12, 60) 27 (12, 60) 60 (12, 60) 25 (12, 60)
Individuals were dispersed evenly across US regions: 23% northeast, 24% north-central, 30% south, 21% west, and 2% unknown (commercial/Medicare analysis) and matched very closely in the
Medicaid analysis (1%-2% variation per geography).
August 2016 ORIGINAL ARTICLESage-cohort from $1000 to $10 000, with an all-age mean
of $6801 for commercial/Medicare supplemental and $4220
for Medicaid (Figure 1).
Patients with PWS ages 5-17 years had the greatest medi-
cation costs, due largely to the use of rhGH therapy. The
top 5 therapeutic medication categories most frequently pre-
scribed to individuals with PWS included: (1) hormones and
synthetic hormone substitutes; (2) central nervous system
agents; (3) anti-infective agents; (4) cardiovascular agents;
and (5) gastrointestinal agents. Hormones and synthetic hor-
mone substitutes constituted the vast majority of the costs
(78% commercial/Medicare supplement, 54% Medicaid)
and decreased slightly in prescription frequency with
increasing age cohort (peak utilization ages 5-11 years). Cen-
tral nervous system and cardiovascular agents were used with
increasing frequency in older PWS (and without PWS) age
cohorts (Figure 2).
Inpatient care costs across all ages were 10.7 times greater
for commercially insured patients with PWS and 4.8 times
greater for Medicaid-insured patients with PWS compared
with individuals without PWS. The mean cost for inpatient
admissions varied by age cohort from $3000 to $26 000
PPPY, with an all-age mean of $10 879 for commercial and
$8727 for Medicaid insured patients (Figure 1). The PWS
0-1 years of age cohort had the greatest inpatient admission
costs (mean $26 270 and $20 291 for commercial and
Medicaid patients with PWS, respectively), likely due to
complicated neonatal care.
Driving these costs, inpatient admission frequency and
length of stay (LOS) were greater in the population with
PWS compared with the population without PWS. Commer-
cially insured patients with and without PWS had 0.28 and
0.05 inpatient admissions PPPY, with a mean LOS of 2.73The High Direct Medical Costs of Prader-Willi Syndromeand 0.23 days PPPY, respectively. Medicaid-insured patients
with and without PWS had 0.33 and 0.16 inpatient admis-
sions PPPY, with a mean LOS of 3.62 and 0.86 days PPPY,
respectively.
Mean PPPY costs for outpatient care (eg, office visits,
outpatient procedures, therapy, and some medical equip-
ment and supplies) were 6.1 times greater ($11 032 vs
$1804) for commercially insured patients and 9.5 times
greater ($27 921 vs $2928) for Medicaid-insured patients
(all-age, ratio of PWS to without PWS). These costs varied
by age cohort (Figure 1). In the commercially insured
population, outpatient costs were greatest in both young
childhood and adult age cohorts (0-4 years and 26+ years).
In the Medicaid-insured population, outpatient costs rose
precipitously with increasing age cohort, to greater than
$35 000 for patient cohorts older than 18 years of age.
Of note, the frequency of Medicaid outpatient encounters
for patients with and without PWS increased significantly in
older age cohorts (18+). On investigating this trend further,
we found that the increase was attributable primarily to day
and residential habilitation Medicaid waivers, accounting for
50% of Medicaid outpatient costs for individuals over 18
years (Figure 3).
Mean all-cause total care costs were 8.8 times greater
($28 712 vs $3246) for commercially insured patients and
7.7 times greater ($40 868 vs $5306) forMedicaid-insured pa-
tients (all-age, ratio of PWS to without PWS). The mean total
cost varied by age cohort between $22 000 and $55 000
PPPY (Figure 1). This finding is in stark contrast to the
population without PWS with mean total costs ranging
from under $1000 in younger age cohorts, to a maximum
value of just over $10 000 in the 41+ age cohort. PWS vs
without PWS comparisons for all-cause total costs of care139
Figure 1. A, Mean total costs for individuals with and without PWS by payer type and age cohort. Differences are statistically
significant (P < .0001) for all comparisons of subjects with and without PWS. B, High cost ratios demonstrate the high disparity
between health care costs of subjects with andwithout PWS. The greatest disparity occurs between ages 2-17 years, as patients
with PWS incur heavy healthcare utilization, particularly compared with their controls, composed largely of individuals without
PWS or other comorbidities. C,Mean component costs for patients with PWS by payer type and age cohort. Outpatient claims
comprise the largest cost driver overall (“All Ages”) and are especially pronounced in Medicaid patients older than 18 years of
age. Inpatient claims are the largest contributor to costs for individuals with PWS age 0-1 year of age. Medication costs are at
their greatest level for individuals between ages 5-17 years of age.
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The greatest cost disparity (as demonstrated by PWS to
without PWS cost ratios) occurs in the younger age
populations (Figure 3).
Discussion
Results from this analysis of US commercial, Medicare sup-
plemental, and Medicaid administrative claims suggest that
total, medication, inpatient, and outpatient medical resource
use was considerably greater among patients with PWS than
their matched controls without PWS. Specifically, we found140that synthetic hormones, predominantly rhGH, were a lead-
ing driver of medication costs in the population with PWS,
particularly in the 5-17 years of age cohort. We also found
that costs for inpatient admissions (relatively infrequent for
patients with and without PWS) were explained by a few in-
dividual admissions or episodes of care and were especially
pronounced in the 0-1 years of age neonatal cohort. Outpa-
tient care costs contributed the largest portion of total direct
medical costs for patients with PWS. Although a portion of
outpatient care costs were attributable to planned procedures
such as spinal fusion (scoliosis) surgery, particularly high
costs also were observed for unplanned admissions, forShoffstall et al
Figure 2. More than one-half of individuals with PWS had at least one claim for a hormone agent, a number that declined slightly
with increasing age cohort. CNS and cardiovascular agents were used with increasing frequency by older age cohorts. The dif-
ference in all-age drug exposure frequency between individuals with and without PWS and was statistically significant for each
class of agents shown (hormone, CNS agents, and cardiovascular agents), P < .0001. CNS, central nervous system.
August 2016 ORIGINAL ARTICLESexample, for respiratory distress (tracheostomies with me-
chanical ventilation). Finally, our analyses indicated that
outpatient care costs were disproportionately high for
Medicaid patients with PWS compared with patients with
PWS with commercial or Medicare supplemental insurance.
The high rate of Medicaid outpatient costs was attributable
primarily to day and residential habilitation Medicaid
waivers that accounted for 50% of Medicaid outpatient
costs for individuals with PWS older than 18 years of age.
Heavyhealthcare utilization iswell-recognized in certain ge-
netic disorders, such asDown syndrome. In a previous studyof
health care costs in a pediatric (age 0-4 years) Down syndrome
population, average annual inpatient, outpatient, and pre-
scription medication costs were $21 842, $13 594, and $927
respectively.13 These high costs are driven primarily by
congenital heart disorders that commonlymanifest inmedical
resource utilization in the first years of life. Althoughmuch less
recognized as a high burden condition, patients with PWS ages
0-4 years accrue costs of similar magnitude.13
In a Dutch study on use of medical care and prevalence of
serious illness in adult cohort with PWS, the authors reported
similar types of medical utilization with regard to hospital
admissions and medication use; however, costs were not
captured, and the sample was limited to 102 individuals
with PWS.14 In another study of fragile X syndrome, SaccoThe High Direct Medical Costs of Prader-Willi Syndromeet al15 also observed greater Medicaid outpatient costs
(mean $12 608) compared with commercial/Medicare costs
($4643). In their case, claims for case management services
appeared to be driving the discrepancy.15 Mean total costs
they presented for individuals with fragile X syndrome
($5700-$8800 commercial/Medicare, $10 500-$23 000
Medicaid, 2004-2009 dollars) were comparable with those
we presented for individuals with PWS.
This study has a number of important limitations. First,
the identification of patients in administrative claims studies
relies on the association of ICD-9-CM codes used for billing
of services. As a result, the disproportionately small number
of older adult patients with PWS (>41 years of age) observed
in this dataset was likely due to PWS coding behavior rather
than actual trends in utilization or population composition.
We surmise that the further a patient is from his/her original
PWS diagnosis, the less likely that his/her medical record will
reflect that diagnosis. Of note, the same age distribution
trend was observed in a similar study of fragile X syndrome,
a disorder also primarily diagnosed in infancy.15
Second, we observed a longer continuous enrollment
period in the group with PWS compared with the group
without PWS, which may reflect the fact that patients with
chronic conditions retain their health insurance carrier
longer. To adjust for differing patient follow-up lengths of141
Figure 3. A, Frequency of outpatient services (PPPY). The number of claims for Medicaid outpatient services increased dras-
tically for individuals in older age cohorts. B, Four Healthcare Common Procedure Coding System codes (T2014, T2016, T2020,
T2021) used for Medicaid habilitation waivers comprised a large percentage of Medicaid outpatient costs.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 175time and to produce equally weighted metrics, analyses were
calculated on a PPPY basis.
Finally, administrative claims only reflect billed health care
services and thus do not capture innumerable nonmedical
and indirect services or resources consumed by patients
and caregivers. Health care workers and caregivers that
manage PWS recognize it as a highly burdensome condition,
encompassing direct nonmedical costs (eg, food access pre-
vention, family care), productivity costs (eg, reduced earning
potential of patient and caregiver), and psychosocial costs
(eg, social isolation, stress).6,7,16 A broader look at all cost cat-
egories is warranted in future research, but because our re-
sults report specifically on the direct medical costs
associated with PWS, they likely vastly understate the overall
societal burden of the disorder.
Interestingly, our analysis yielded lower medication costs
than expected. At time of publication, an average wholesale
price for rhGH was $100 per milligram.17 At doses ranging
from 0.16 to 0.24 mg/kg-week (assuming a body weight of
35 kg), the expected costs are in the range of $29 120 to142$43 680 for individuals receiving this medication, which is
significantly greater than our mean prescription medication
cost findings. On further investigation, we discovered that
only 50% of patients had at least 1 claim for a growth hor-
mone or other synthetic hormone substitute. This rate is low
compared with published guidelines.18 There may be many
important clinical factors influencing the apparently low
rate of rhGH prescriptions, including proper prescribing,
dosing, and usage of rhGH in this population with PWS, as
well as patient compliance and adherence, which would be
reflected in data captured here. Other explanations for the
discrepancy, however, also may be related to medications be-
ing covered by other pharmacy “carve-out” benefits and/or
dual coverage from multiple payers (eg, some patients may
receive both commercial and Medicaid benefits) that are
not captured in this dataset.
Because PWS is rare, its overall financial impact is likely
modest compared with other conditions. That PWS-related
costs are so drastically and disproportionately high compared
with individuals without PWS, however, speaks to the needShoffstall et al
August 2016 ORIGINAL ARTICLESfor effective treatments to improve patient survival and qual-
ity of life and to reduce the financial burden on patients and
families. n
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